MDX-1401

Bristol-Myers Squibb · Phase 1 active Biologic

At a glance

Generic name	MDX-1401
Sponsor	Bristol-Myers Squibb
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MDX-1401 CI brief — competitive landscape report
MDX-1401 updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI